EHA Library - watch selected Congress content

On the EHA Library, you can find educational resources and browse open-source material from past EHA Congresses and Meetings. You can already browse the EHA2024 Congress abstracts and select content on the EHA Library.

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

What can I expect?

Learning objectives


Discuss the principles of translational research design and execution. Recognize the ethical and regulatory issues of translational research. Examine the fundamentals of competitive grant writing, abstract presentation, and manuscript preparation.

Season's Greetings

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

EHA to the European Commission and HTA leaders: work with medical societies to involve experts and make joint assessments a success

The speakers of the HTA conference hosted by the European Commission.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).